Testing a clot-busting drug coated with platelet membranes
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study tests a new way to deliver a clot-dissolving drug called tenecteplase. The drug is coated with platelet membranes to target blood clots in arteries. It may offer a safer, more effective treatment for heart attack patients and is also enrolling healthy volunteers for comparison.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and weigh at least 99 pounds (45 kg).
- For people with heart disease: You are scheduled for a heart catheterization and have been taking aspirin and ticagrelor for at least 3 days, or had a high dose at least 12 hours before.
- For healthy volunteers: You are not taking any medications that affect bleeding, such as blood thinners or ibuprofen.
- You must not have diabetes (for healthy volunteers) or be a smoker (for healthy volunteers).
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a clot-busting drug called tenecteplase works safely in people having a stroke who are already taking certain blood-thinning medications (like apixaban or rivaroxaban). The goal is to see if it can restore blood flow to the brain better than current treatments.
This trial tests a clot-busting drug called tenecteplase, given directly into the blocked artery, for people who have had a stroke caused by a medium-sized brain vessel blockage within the last 24 hours. It aims to see if this treatment is safe and effective in improving recovery.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the brain artery after a successful mechanical clot removal can improve recovery for people with a certain type of stroke. The goal is to see if it safely helps clear any remaining tiny clots and reduces disability.
This study tests a clot-dissolving drug called tenecteplase given directly into the artery after a mechanical thrombectomy (clot removal). The goal is to see if it helps improve blood flow to the small vessels in the brain after the main clot is removed.
This study tests a medication called tenecteplase, given before a procedure to remove a large blood clot in the brain. It may help people who have had a severe stroke within the last 4.5 hours.
Hear when a new Arterial Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.